ZA200409908B - Use of MgIuR5 antagonists for the treatment of GERD - Google Patents
Use of MgIuR5 antagonists for the treatment of GERD Download PDFInfo
- Publication number
- ZA200409908B ZA200409908B ZA200409908A ZA200409908A ZA200409908B ZA 200409908 B ZA200409908 B ZA 200409908B ZA 200409908 A ZA200409908 A ZA 200409908A ZA 200409908 A ZA200409908 A ZA 200409908A ZA 200409908 B ZA200409908 B ZA 200409908B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonist
- glutamate receptor
- metabotropic glutamate
- substance
- composition
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 74
- 208000021302 gastroesophageal reflux disease Diseases 0.000 title claims abstract description 21
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims abstract description 69
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims abstract description 20
- 230000005764 inhibitory process Effects 0.000 claims abstract description 17
- 208000006673 asthma Diseases 0.000 claims abstract description 14
- 230000001052 transient effect Effects 0.000 claims abstract description 12
- 206010067171 Regurgitation Diseases 0.000 claims abstract description 9
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims abstract 36
- 238000000034 method Methods 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 40
- 230000002265 prevention Effects 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 27
- 230000003287 optical effect Effects 0.000 claims description 25
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical group CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- NBFUGBSVJORKJO-UHFFFAOYSA-N 3-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile Chemical group COCC1=CC(C#N)=CC(C=2ON=C(N=2)C=2N=CC(F)=CC=2)=C1 NBFUGBSVJORKJO-UHFFFAOYSA-N 0.000 claims description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 6
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- 206010016165 failure to thrive Diseases 0.000 claims description 6
- 201000008197 Laryngitis Diseases 0.000 claims description 5
- 201000009243 chronic laryngitis Diseases 0.000 claims description 5
- RBSPCALDSNXWEP-UHFFFAOYSA-N 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile Chemical group N1=CC(F)=CC=C1C1=NOC(C=2C=C(C=C(F)C=2)C#N)=N1 RBSPCALDSNXWEP-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims 32
- 239000003512 metabotropic receptor antagonist Substances 0.000 claims 3
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 19
- 238000001802 infusion Methods 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- -1 mGIluR3 Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 241000167880 Hirundinidae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 2
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 2
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 2
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 2
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000005477 standard model Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- JMUPRKJXQQILFI-UHFFFAOYSA-N 2-(methoxymethyl)benzonitrile Chemical compound COCC1=CC=CC=C1C#N JMUPRKJXQQILFI-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100022197 Glutamate receptor ionotropic, kainate 1 Human genes 0.000 description 1
- 101710112359 Glutamate receptor ionotropic, kainate 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000016752 upper digestive tract disease Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201943A SE0201943D0 (sv) | 2002-06-20 | 2002-06-20 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200409908B true ZA200409908B (en) | 2006-08-30 |
Family
ID=20288301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200409908A ZA200409908B (en) | 2002-06-20 | 2004-12-07 | Use of MgIuR5 antagonists for the treatment of GERD |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1513525B1 (enExample) |
| JP (2) | JP4683920B2 (enExample) |
| CN (1) | CN100430056C (enExample) |
| AT (1) | ATE395059T1 (enExample) |
| AU (1) | AU2003241585B2 (enExample) |
| BR (1) | BR0311759A (enExample) |
| CA (1) | CA2489730C (enExample) |
| CY (1) | CY1107954T1 (enExample) |
| DE (1) | DE60320990D1 (enExample) |
| DK (1) | DK1513525T3 (enExample) |
| ES (1) | ES2304510T3 (enExample) |
| IL (1) | IL165138A0 (enExample) |
| IS (1) | IS7654A (enExample) |
| MX (1) | MXPA04012659A (enExample) |
| NO (1) | NO20050154L (enExample) |
| NZ (1) | NZ536559A (enExample) |
| PL (1) | PL372186A1 (enExample) |
| PT (1) | PT1513525E (enExample) |
| RU (1) | RU2324484C2 (enExample) |
| SE (1) | SE0201943D0 (enExample) |
| SI (1) | SI1513525T1 (enExample) |
| UA (1) | UA81627C2 (enExample) |
| WO (1) | WO2004000316A1 (enExample) |
| ZA (1) | ZA200409908B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964609B2 (en) | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
| SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| WO2005060961A2 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077368A2 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| AU2005214376A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists |
| SG149900A1 (en) * | 2004-02-18 | 2009-02-27 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| GB0514296D0 (en) * | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
| MX2008012413A (es) * | 2006-03-29 | 2008-10-07 | Hoffmann La Roche | Derivados de piridina y pirimidina como antagonistas del receptor metabotropico de glutamato 2 (mglur2). |
| EP2272509A1 (en) | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| JP2008245225A (ja) * | 2007-03-29 | 2008-10-09 | Kddi Corp | 波長パス経路決定装置、波長パス設定制御システム及びプログラム |
| WO2009024491A1 (en) * | 2007-08-20 | 2009-02-26 | F. Hoffmann-La Roche Ag | Use of mglur5 antagonists for the treatment of gerd |
| WO2010000763A2 (en) | 2008-06-30 | 2010-01-07 | Novartis Ag | Combination products |
| EP2456438A2 (en) | 2009-07-23 | 2012-05-30 | Novartis AG | Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| WO2011048150A1 (en) | 2009-10-20 | 2011-04-28 | Novartis Ag | Use of 1h-quinazoline-2,4-diones |
| CA2800970A1 (en) | 2010-06-24 | 2011-12-29 | Novartis Ag | Use of 1h-quinazoline-2,4-diones |
| US20140171448A1 (en) | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| CA2846503A1 (en) | 2011-09-07 | 2013-03-14 | Novartis Ag | Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy |
| JP6137336B2 (ja) | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用 |
| MX379289B (es) | 2013-01-15 | 2025-03-10 | Novartis Ag | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. |
| EP4007575B1 (en) * | 2019-11-05 | 2023-09-27 | Claes THULIN | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987004077A1 (en) * | 1986-01-03 | 1987-07-16 | The University Of Melbourne | Gastro-oesophageal reflux composition |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| JP2002515448A (ja) * | 1998-05-15 | 2002-05-28 | アフトン・コーポレーシヨン | 食道逆流病の処置法 |
| RU2144331C1 (ru) * | 1998-11-05 | 2000-01-20 | Московский НИИ уха, горла и носа | Способ лечения хронического гиперпластического ларингита |
| ATE307129T1 (de) * | 1999-08-19 | 2005-11-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren |
| CN1703403A (zh) * | 2000-10-02 | 2005-11-30 | 詹森药业有限公司 | 趋代谢的谷氨酸盐受体拮抗剂 |
-
2002
- 2002-06-20 SE SE0201943A patent/SE0201943D0/xx unknown
-
2003
- 2003-06-19 DE DE60320990T patent/DE60320990D1/de not_active Expired - Lifetime
- 2003-06-19 WO PCT/US2003/016223 patent/WO2004000316A1/en not_active Ceased
- 2003-06-19 MX MXPA04012659A patent/MXPA04012659A/es not_active Application Discontinuation
- 2003-06-19 JP JP2004515703A patent/JP4683920B2/ja not_active Expired - Fee Related
- 2003-06-19 AU AU2003241585A patent/AU2003241585B2/en not_active Ceased
- 2003-06-19 PL PL03372186A patent/PL372186A1/xx not_active Application Discontinuation
- 2003-06-19 UA UA20041210177A patent/UA81627C2/ru unknown
- 2003-06-19 NZ NZ536559A patent/NZ536559A/en not_active IP Right Cessation
- 2003-06-19 DK DK03731333T patent/DK1513525T3/da active
- 2003-06-19 EP EP03731333A patent/EP1513525B1/en not_active Expired - Lifetime
- 2003-06-19 ES ES03731333T patent/ES2304510T3/es not_active Expired - Lifetime
- 2003-06-19 AT AT03731333T patent/ATE395059T1/de active
- 2003-06-19 RU RU2005101411/15A patent/RU2324484C2/ru not_active IP Right Cessation
- 2003-06-19 BR BR0311759-6A patent/BR0311759A/pt not_active IP Right Cessation
- 2003-06-19 CA CA2489730A patent/CA2489730C/en not_active Expired - Fee Related
- 2003-06-19 PT PT03731333T patent/PT1513525E/pt unknown
- 2003-06-19 CN CNB038141760A patent/CN100430056C/zh not_active Expired - Fee Related
- 2003-06-19 SI SI200331220T patent/SI1513525T1/sl unknown
-
2004
- 2004-11-10 IL IL16513804A patent/IL165138A0/xx unknown
- 2004-12-07 ZA ZA200409908A patent/ZA200409908B/en unknown
-
2005
- 2005-01-11 NO NO20050154A patent/NO20050154L/no not_active Application Discontinuation
- 2005-01-19 IS IS7654A patent/IS7654A/is unknown
-
2008
- 2008-05-21 CY CY20081100527T patent/CY1107954T1/el unknown
-
2010
- 2010-12-01 JP JP2010268162A patent/JP2011068669A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK1513525T3 (da) | 2008-08-11 |
| MXPA04012659A (es) | 2006-05-25 |
| ATE395059T1 (de) | 2008-05-15 |
| CY1107954T1 (el) | 2013-09-04 |
| RU2324484C2 (ru) | 2008-05-20 |
| IS7654A (is) | 2005-01-19 |
| SE0201943D0 (sv) | 2002-06-20 |
| BR0311759A (pt) | 2005-03-08 |
| RU2005101411A (ru) | 2005-07-10 |
| AU2003241585A1 (en) | 2004-01-06 |
| IL165138A0 (en) | 2005-12-18 |
| PT1513525E (pt) | 2008-06-24 |
| HK1075833A1 (en) | 2005-12-30 |
| PL372186A1 (en) | 2005-07-11 |
| NO20050154L (no) | 2005-01-11 |
| AU2003241585B2 (en) | 2009-06-25 |
| UA81627C2 (ru) | 2008-01-25 |
| JP2011068669A (ja) | 2011-04-07 |
| EP1513525A1 (en) | 2005-03-16 |
| CA2489730C (en) | 2011-11-22 |
| NZ536559A (en) | 2007-08-31 |
| CA2489730A1 (en) | 2003-12-31 |
| DE60320990D1 (de) | 2008-06-26 |
| EP1513525B1 (en) | 2008-05-14 |
| CN100430056C (zh) | 2008-11-05 |
| SI1513525T1 (sl) | 2008-08-31 |
| WO2004000316A1 (en) | 2003-12-31 |
| JP2006507225A (ja) | 2006-03-02 |
| JP4683920B2 (ja) | 2011-05-18 |
| CN1662235A (zh) | 2005-08-31 |
| ES2304510T3 (es) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003241585B2 (en) | Use of mGluR5 antagonists for the treatment of GERD | |
| Velasco et al. | Dopamine: pharmacologic and therapeutic aspects | |
| WO2005077373A2 (en) | Treatment of gastro-esophageal reflux disease (gerd) | |
| PL191073B1 (pl) | Zastosowanie kombinacji antagonistów receptorów histaminowych H1 i H3 | |
| KR20140030237A (ko) | 벤즈이미다졸 유도체를 함유하는 고체 약제학적 조성물 | |
| US20040266861A1 (en) | Use for the treatment of gastroesophageal reflux disease | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| JP2008156297A (ja) | セロトニン２ｂおよび／または２ｃ受容体拮抗剤 | |
| US7964609B2 (en) | Use of mGluR5 antagonists for the treatment of gerd | |
| JPWO2006118212A1 (ja) | 膵炎の予防および治療剤 | |
| HK1075833B (en) | Use of mglur5 antagonists for the treatment of gerd | |
| JP6797691B2 (ja) | ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途 | |
| WO2005058361A1 (en) | USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD | |
| AU2002328569B9 (en) | Medicinal compositions containing angiotensin II receptor antagonist | |
| KR20050024351A (ko) | Ｇｅｒｄ 치료용 ｍｇｌｕｒ５ 길항제의 용도 | |
| JP4677191B2 (ja) | 過敏性腸症候群処置剤 | |
| WO2005058326A1 (en) | USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) | |
| US20050222263A1 (en) | Compositions against stress-related diseases and methods for treating stress-related diseases | |
| JPH0672876A (ja) | 末梢血管抵抗改善による血圧降下剤 | |
| AU9703601A (en) | Method for treating chronic obstructive pulmonary disease | |
| JPH0827029A (ja) | ５ｈｔ１ 作動薬の新規医薬用途 | |
| JP2007514788A (ja) | 過敏性腸症候群の新規な処置ｉ | |
| WO2002042765A1 (fr) | Remedes destines a des troubles fonctionnels digestifs et procede de selection | |
| HK1083587A1 (en) | Body weight gain inhibitor |